Pure Global AI
NCT06287164Recruiting

Management of Heart Failure in Italian Outpatients Clinics: Observational Study

Optimization of Therapy in the Italian Management of Heart Failure: OPTIMA-HF Observational Study
Federico II UniversityClinicalTrials.govother
Study focus
Disease/Condition
Heart Failure
Drug/Device/Intervention
Data collection
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
Federico II University
Location
Napoli, Italy
Timeline & enrollment
Phase
N/A
Start date
Mar 01, 2023
End date
Feb 01, 2025
Enrollment
4000 participants
Primary outcome

HF treatment adherence according to the most recent European Guidelines

Summary

OPTIMA-HF is an observational, cross-sectional, multicenter, real-life study conducted in two
 different clinical settings: HF outpatients' clinics of Italian University Hospitals and
 territorial Cardiology outpatients' services.
 
 Aim of the Optimization of Therapy in the Italian Management of Heart Failure [OpTIMa-HF]
 Registry is to collect data on HF patients followed in different Italian outpatients'
 settings to describe the current Italian population of HF patients, in terms of demographic
 characteristics and disease features, with a specific focus on guideline-directed medical
 therapy (GDMT) prescription, assessing its improvement after educational activities. In the
 present analysis we report the baseline data on the general enrolled population with a
 specific focus on HFrEF treatment adherence and prescription rates, according to the most
 recent European Guidelines.

ICD-10 classifications
Heart failureHeart failure, unspecifiedCongestive heart failureHypertensive heart disease with (congestive) heart failureLeft ventricular failure
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06287164
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06287164 through Pure Global AI's free database. This phase not specified trial is sponsored by Federico II University and is currently Recruiting. The study focuses on Heart Failure. Target enrollment is 4000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.